MorphoSys AG (ETR:MOR – Get Free Report) shares traded down 0.6% during mid-day trading on Monday . The company traded as low as €66.65 ($74.06) and last traded at €66.80 ($74.22). 5,794 shares traded hands during trading, a decline of 96% from the average session volume of 153,687 shares. The stock had previously closed at €67.20 ($74.67).
MorphoSys Stock Down 0.6 %
The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.08, a P/E/G ratio of 0.06 and a beta of 0.66. The business’s 50-day moving average is €67.53 and its two-hundred day moving average is €66.59. The company has a debt-to-equity ratio of 3,454.18, a quick ratio of 3.49 and a current ratio of 1.38.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.
Recommended Stories
- Five stocks we like better than MorphoSys
- How to invest in marijuana stocks in 7 steps
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- 3 Small Caps With Big Return Potential
- 2 Option Strategies to Maximize Profits in a Bear Market
- Investing in Construction Stocks
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.